Global In vivo Toxicology Market:Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Increasing R&D activities in the pharmaceutical industry and rising COVID-19 cases are the major factors driving the growth of Global In vivo Toxicology Market.
Global In vivo Toxicology Market is valued at USD 4981.2 Million in 2020 and expected to reach USD 7255.7 Million by 2027 with a CAGR of 5.52% over the forecast period.
Toxicology helps to understand the harmful effects that chemicals, substances, or situations, can have on people, animals, and the environment. Effects of chemicals or physical agents on living organisms called as Toxicology. Body, an organ, a type of cell or a specific medical can be affected by these changes. Research studies performed inside an integral, living organisms like a research center creature, to comprehend the toxic impacts of different chemical substances managed in the test subject are called in vivo toxicology. Rabbits, rats, guinea pigs, hamsters, mice, and so on are the different test subjects on which these chemicals can be controlled. Animal models are used for research effort to decrease the bad side effects and exploit the therapeutic properties of a drug before it is taken for clinical trials. In the process of drug discovery genetically engineered mouse models plays a critical role.
Research on these genetically engineered mouse models facilitates the study and characterization of disease pathology, target toxicity experiments may be conducted in vivo (using the whole animal) or in vitro (testing on isolated cells or tissues), or in silico (in a computer simulationidentification, and in vivo evaluation of novel therapeutic agents and treatments. Types of toxicology are medical toxicology, clinical toxicology, forensic toxicology, computational toxicology, and occupational toxicology. Applications of in vivo toxicology are to monitor pathogenesis of disease by comparing the consequences of bacterial infection with the effects of purified bacterial toxins; the expansion antibiotics, antiviral drugs, and new drugs and new surgical measures.
The COVID-19 pandemic has shown a positive impact on the growth of global in vivo toxicology market. As the increasing COVID-19 cases day by day, there was panic in public and challenges to researchers to invent a good treatment and vaccine. Due to this there is growing focus on vaccine development. During these vaccine studies the in vivo toxicology helped in the preclinical phase, and some of them have already entered the animal trial phase. Several animal models, are used for vaccine trials particularly mice models which have supported the replication of SARS-CoV-2. These factors augmented the growth of global in vivo toxicology market during covid-19 pandemic.
Global in vivo toxicology market is segmented on the basis of testing facility, test type, toxicity endpoints, end-user type and region & country level. Based on testing facility, in vivo toxicology market is divided into out-source testing facility and in-house testing facility. Based on test type, the market is classified into acute, sub-acute, sub-chronic and chronic. Based on toxicity endpoints, in vivo toxicology market is divided into immunotoxicity, genotoxicity, systemic toxicity, carcinogenecity, development & reproductive toxicity (DART) and others. Based on end-user, the market is divided into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations and other.
The regions covered in global in vivo toxicology market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of g global in vivo toxicology is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some major key players for global in vivo toxicology market report cover prominent players like Charles River Laboratories, The Jackson Laboratory, Envigo, Taconic Biosciences, Inc., and JANVIER LABS, Thermo Fisher Scientific, Danaher Corporation, Waters Corporation, Agilent Technologies, Shimadzu Corporation, Bruker Corporation, PerkinElmer and others.
On July 19th, 2021; Altogen Biosystems announced that Altogen's nanoparticle-situated in vivo Transfection reagent (item inventory #5031) was shown to be viable for glioblastoma-designated co-conveyance of plasmid DNA (3.7kb) and chemically altered siRNA. The nanoparticle-situated in vivo transfection kit showed high transfection productivity into glioblastoma tissue in both unconstrained and chemically instigated murine glioma syngeneic mouse models (GL26 and P560). The nanometer-sized particles are equipped for intersection the capillary walls and are efficiently endocytosed by glioblastoma cells. This transfection reagent was utilized in more than 30 examination distributions, showing profoundly effective delivery of cargo nucleic acids to the follow tissues: liver, lung, heart, pancreas, kidney, and different cancer types. To empower powerful delivery of little RNA and plasmid DNA into glioblastoma tissue, Altogen researchers created and changed transfection protocol.
One of the major factors driving the growth of global in vivo toxicology market is increasing R&D activities in the pharmaceutical industry. A rising number of pharma organizations and clinical device manufacturing centers on advancement and their increasing R&D efficiencies. The essential objective of R&D is to improve the general probability of approval of Phase I competitors by expanding the acknowledgment of the compounds in the preclinical stages. To accomplish this, intensive R&D is led in the beginning phases of drug advancement. Growing R&D investments in the early phases of drug development are probably going to build the utilization of in vivo toxicology strategies before the drug arrives at the more costly clinical stage.
For instance; as indicated by the NY Times, researchers are as of now testing 89 vaccines in clinical preliminaries on people and 23 have arrived at the last phases of testing. Also, somewhere around 77 vaccines are under active examination in animals.
In addition, rising cases of Covid-19 also supplementing the growth of global in vivo toxicology market. The Covid-19 pandemic is an uncommon worldwide public health challenge that is relied upon to significantly affect the in vivo toxicology market, particularly because of the developing focus on vaccine advancement. For instance; according to the World Health Organization (WHO), in excess of 20 vaccines are being created across the globe for COVID-19.
Furthermore, increasing advancements in the field of animal models are also fostering the market growth. Little animals like rats and mice are generally utilized mammalian model systems because of their little size, short regenerative cycle, simplicity of maintenance and handling, sharing of genomic and physiological properties with people and capacity to be promptly controlled genetically. One of the finest mouse models utilized for Covid-19 is the K18-hACE2 transgenic mouse. A few different models used to test for different impacts of the infection on mice are the AC70 transgenic mice, hCAE2 Tg mice. A faster, reproducible murine model for SARS-CoV-2 was the Adeno-associated virus (AAV) conveyance based mouse model.
However, availability of other alternatives may hamper the market growth. In spite of that, rising demand for humanized animal model and focus on personalized medicine may offer more opportunities for the further growth of the global in vivo toxicology market.
North America is expected to dominate the market of global in vivo toxicology market due to the rising investments R&D, increasing preclinical activities and presence of key players in this region. For instance; as indicated by the Biotechnology Industry Organization (BIO) 2019, almost 82.7% of the funding investments in the US by emerging growth companies (EGCs) in the course of the last decade were in R&D for arising therapeutics and novel medications. Moreover, approximately 50% of the funding investment for therapeutics was intended for developing biologic atoms/metabolites.
Asia Pacific is expected to witness a lucrative growth in global in vivo toxicology market due to the increasing focus of government organizations to promote toxicology testing by in-vivo methods and development in healthcare infrastructure. There are clinical trials which are less cost-effective as compared to western nations, thus biopharmaceutical companies prefer to perform their drug development procedures in this region.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 4981.2 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 7255.7 Million|
|Tables, Charts & Figures:||175|
|Key Players/Companies||Charles River Laboratories, The Jackson Laboratory, Envigo, Taconic Biosciences, Inc., and JANVIER LABS, Thermo Fisher Scientific, Danaher Corporation, Waters Corporation, Agilent Technologies, Shimadzu Corporation, Bruker Corporation, PerkinElmer and others.|
|Segments Covered||By Testing Facility, By Test Type, By Toxicity Endpoint, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|